Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - COR Therapeutics, Inc. (NasdaqNM:CORR)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Location
256 East Grand Avenue
South San Francisco, CA 94080
Phone: (650) 244-6800
Fax: (650) 244-9208
Email: feedback@corr.com
Employees (last reported count): 311
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Index Membership
 ·S&P 400 MidCap
Ownership
·Insider and 5%+ Owners: 25%
·Over the last 6 months:
 · 3 insider sells; 32.0K shares
  (0.2% of insider shares)
·Institutional: 87% (116% of float)
(371 institutions)
·Net Inst. Buying: 4.67M shares (+8.77%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
COR Therapeutics, Inc. is engaged in the discovery, development and marketing of novel therapeutic products to establish new standards of care for treating and preventing acute and chronic cardiovascular diseases. The Company is marketing Integrilin, its FDA-approved drug, to treat patients with acute cardiovascular disease. The Company is also developing a portfolio of drugs to treat and prevent a broad range of acute and chronic cardiovascular diseases and other conditions. In addition to its commercial activities, the Company continues to pursue a wide array of research and development programs that may have therapeutic potential for a variety of indications, including acute coronary syndromes, stroke, restenosis, cancer, and venous and arterial thrombosis.
More from Market Guide: Expanded Business Description

Financial Summary
COR Therapeutics, Inc. is engaged in the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. For the six months ended 6/30/01, revenues rose 42% to $60.8 million. Net income totaled $452 thousand vs. a loss of $16.4 million. Results reflect continued strong demand for INTEGRILIN, improved operating margins and increased interest income.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Vaughn Kailian, 56
Pres, CEO
$784K$4.9M
Charles Homcy, M.D., 52
Exec. VP of R&D
521K8.5M
Peter Roddy, 41
Sr. VP-Fin., CFO
--  --  
Patrick Broderick, 42
Sr. VP, Gen. Counsel and Corp. Sec.
365K3.3M
Lee Rauch, 47
Sr. VP, Corp. Devel.
378K1.2M
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CORRAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$17.50 
Recent Price$27.45 
52-Week High
on 25-Sep-2000
$67.25 
Beta0.90 
Daily Volume (3-month avg)997.7K
Daily Volume (10-day avg)705.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-51.4%
52-Week Change
relative to S&P500
-34.8%
Share-Related Items
Market Capitalization$1.52B
Shares Outstanding55.5M
Float41.7M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 16-Aug-2000
Per-Share Data
Book Value (mrq)$0.96 
Earnings (ttm)-$0.00 
Earnings (mrq)$0.06 
Sales (ttm)$2.15 
Cash (mrq)$10.39 
Valuation Ratios
Price/Book (mrq)28.58 
Price/EarningsN/A 
Price/Sales (ttm)12.76 
Income Statements
Sales (ttm)$122.6M
EBITDA (ttm)-$2.39M
Income available to common (ttm)$239.0K
Profitability
Profit Margin (ttm)0.2%
Operating Margin (ttm)-5.1%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)0.05%
Return on Equity (ttm)0.52%
Financial Strength
Current Ratio (mrq)7.66 
Debt/Equity (mrq)10.35 
Total Cash (mrq)$577.0M
Short Interest
As of 8-Aug-2001
Shares Short7.06M
Percent of Float16.9%
Shares Short
(Prior Month)
7.08M
Short Ratio8.64 
Daily Volume817.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.